Literature DB >> 16848659

Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection.

Jeffrey A Lieberman1, L Fredrik Jarskog, Dolores Malaspina.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16848659     DOI： 10.4088/jcp.v67n0616

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  8 in total

Review 1.  Antipsychotic drugs for first-episode schizophrenia: a comparative review.

Authors:  Kayvon Salimi; L Fredrik Jarskog; Jeffrey A Lieberman
Journal:  CNS Drugs       Date:  2009-10       Impact factor: 5.749

Review 2.  NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms.

Authors:  Melissa A Snyder; Wen-Jun Gao
Journal:  Schizophr Res       Date:  2019-04-09       Impact factor: 4.939

3.  NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia.

Authors:  Melissa A Snyder; Wen-Jun Gao
Journal:  Front Cell Neurosci       Date:  2013-03-27       Impact factor: 5.505

Review 4.  New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function.

Authors:  Takashi Uehara; Tomiki Sumiyoshi; Masayoshi Kurachi
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

Review 5.  Neuroprotection in Schizophrenia and Its Therapeutic Implications.

Authors:  Yong-Ku Kim; Kyoung-Sae Na
Journal:  Psychiatry Investig       Date:  2017-07-11       Impact factor: 2.505

6.  T-817MA, but Not Haloperidol and Risperidone, Restores Parvalbumin-Positive γ -Aminobutyric Acid Neurons in the Prefrontal Cortex and Hippocampus of Rats Transiently Exposed to MK-801 at the Neonatal Period.

Authors:  Takashi Uehara; Tomiki Sumiyoshi; Tomonori Seo; Tadasu Matsuoka; Hiroko Itoh; Masayoshi Kurachi
Journal:  ISRN Psychiatry       Date:  2012-07-08

7.  The PPARα Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia.

Authors:  Benjamin Rolland; Kevin Marche; Olivier Cottencin; Régis Bordet
Journal:  Schizophr Res Treatment       Date:  2012-05-15

8.  The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index.

Authors:  Daniel Schöttle; Wolfgang Janetzky; Daniel Luedecke; Elmar Beck; Christoph U Correll; Klaus Wiedemann
Journal:  BMC Psychiatry       Date:  2020-02-22       Impact factor: 3.630
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.